ProofPilot and DiMe Partner to Enhance Digital Health in Clinical Trials
ProofPilot has announced a strategic partnership with the Digital Medicine Society (DiMe) to advance digital health in clinical trials, announced in a press release. This collaboration aims to drive the development of innovative digital tools for clinical research, focusing on diverse, accessible, and participant-centered study experiences.
The partnership will utilize ProofPilot's CoPilot platform to enhance study experiences, simplify data collection, and provide streamlined, compliant digital solutions for sites and participants. A key focus of this collaboration is to define and collect physiological signals, behavior traits, and mental health characteristics to train a tool aimed at preventing opioid use disorder (OUD) relapse.
Chris Venezia, CEO of ProofPilot, emphasized the alignment of this partnership with their mission to improve clinical trials through digital innovation. Candice Taguibao, Associate Program Director for DiMe, expressed excitement about working together to implement patient-centered approaches to clinical research and develop a digitally derived tool to help prevent relapse and reduce OUD deaths.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish like Life AI Weekly.
Also, consider following us on social media:
More from: Healthcare & Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more